Cytokinetics Still A Buy After Phase 2 SMA Data

Data presented by Cytokinetics, Inc. CYTK showed CK-107 has the ability to positively impact two different animal models of spinal muscular atrophy.

Rodman & Renshaw’s Joseph Pantginis reiterated a Buy rating on the company, with a price target of $25.

Positive Indications

The analyst mentioned the animal models for CK-107 mimic both adult-onset and intermediate iterations of SMA, with both experiments revealing statistically significant impact on muscular force improvement.

Pantginis believes the data presented is “important in supporting the underlying mechanism of action for CK-107.”

Phase 2 Study

Following this preclinical data, Cytokinetics is scheduled to report data on its Phase 2 SMA study in mid-2017.

“Regarding expectations, this is not a typical black and white Phase 2 study with definitive endpoints. Rather it is geared toward generating hypothesis based on the experimental endpoints in the study in order to help define next steps,” the analyst explained.

The endpoints are meant to assess several metrics associated with muscle function and fatigability, with Pantginis believing the preliminary data suggests these measures would be important for the path ahead.

Following recent approvals for SMA drugs by other pharma companies, the analyst expressed optimism CK-107 had “significant potential” to “work in a complementary manner to these therapies and should not be viewed in a competitive fashion.”

Other Data

Cytokinetics also announced additional positive data from its COSMIC-HF study at the ACC 2017, with the data revealing the first echocardiographic evidence omecamtiv mecarbil might have a statistically significant positive impact on left ventricular, myocardial deformation, one of the factors associated with outcomes in heart failure patients.

Related Link:

Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference

Teva's Stock Inches Higher Amid Cost-Cutting Plan

Posted In: CK-107Joseph Pantginisomecamtiv mecarbilRodman & RenshawSpinal Muscular AtrophyAnalyst ColorBiotechLong IdeasNewsHealth CareReiterationFDAAnalyst RatingsMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.